DOCSLIB.ORG

16233 Wellcomeaw 17-02 27/2/04 10:29 Am Page A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
16233 Wellcomeaw 17-02 27/2/04 10:29 Am Page A1 16233 WellcomeAW 17-02 27/2/04 10:29 am Page a1 Annual Report and Financial Statements 2003 16233 WellcomeAW 17-02 27/2/04 10:29 am Page a2 a2 Heading to go here strapline to go here if required 16233 WellcomeAW 17-02 27/2/04 10:29 am Page 1 THE WELLCOME TRUST ANNUAL REPORT AND FINANCIAL STATEMENTS 2003 Contents Administrative Details 2 Chairman’s Statement 4 Trustee’s Report 6 Auditors’ Report 15 Consolidated Statement of Financial Activities 16 Consolidated Balance Sheet 17 Statement of Financial Activities of the Trust 18 Balance Sheet of the Trust 19 Consolidated Cash Flow Statement 20 Notes to the Financial Statements 21 Committees of the Board of Governors 49 Board of Governors 50 Executive Management 51 16233 WellcomeAW 17-02 27/2/04 10:29 am Page 2 2 Administrative Details The Wellcome Trust (the ‘Trust’) is a Board of Governors The Wellcome Trust is managed day to day charitable trust created in 1936 by the Will Sir Dominic Cadbury (Chairman) by the Executive Board and other Senior of the late Sir Henry Wellcome and now Management shown as follows: Professor Sir Michael Rutter, CBE, MD, FRS, governed by its Constitution, which was FBA, FMedSci (Deputy Chairman) established in February 2001 by a scheme Executive Board of the Charity Commission.The Trust is Professor Adrian Bird, FRS, FMedSci Dr Mark Walport, PhD, FRCP,FMedSci registered under the Charities Act 1993 Professor Martin Bobrow, CBE, DSc Med, (Director) (from 1 June 2003) (registration number 210183). FMedSci Dr Michael Dexter, DSc, FRS, FMedSci The sole trustee (the ‘Trustee’) is Professor Christopher Edwards, MD, FRSE, (Director) (retired 31 March 2003) The Wellcome Trust Limited, a company FMedSci limited by guarantee (registration number Mrs Linda Arter (Director of Finance and 2711000), whose registered office is Professor Julian Jack, PhD, FRS, FMedSci Information Management) 183 Euston Road, London NW1 2BE. Mr Alastair Ross Goobey, CBE Dr Ted Bianco, PhD (Director of Technology The Trustee is governed by its memorandum Transfer) and articles of association.The directors Professor Jean Thomas, CBE, ScD, FRS, (known as Governors) and the Company FMedSci Mr John Cooper (Director of Human Resources Secretary of the Trustee are shown as follows: and Services) Mr Edward Walker-Arnott Dr Rick Fuller, MD (Director of Science Funding) Professor Mark Walport, PhD, FRCP,FMedSci (resigned 12 May 2003) (resigned 24 January 2003) Ms Clare Matterson (Director of Medicine, Society and History) Company Secretary Mr John Stewart Dr Sohaila Rastan, MA, D Phil, FMedSci (Director of Science Funding) (from 3 November 2003) Mr Gary Steinberg (Chief Investment Officer) Other Senior Management Dr Allan Bradley, PhD (Director of the Wellcome Trust Sanger Institute) Dr Lee Elliot Major, PhD (Head of Policy and Communications) (resigned 25 September 2003) Mr David Phillipps, FCA (Head of Finance) All of the above have been in office throughout the year unless otherwise stated. 16233 WellcomeAW 17-02 27/2/04 10:29 am Page 3 THE WELLCOME TRUST ANNUAL REPORT AND FINANCIAL STATEMENTS 2003 3 Principal Advisers John W Bristol & Co. Inc Liontrust Investment Services Limited Auditors Lloyd George Investment Management PricewaterhouseCoopers LLP (Bermuda) Limited Merrill Lynch Investment Managers Limited Bankers HSBC Bank plc Morgan Stanley Dean Witter Investment Management Inc Global Custodian Bank Nordea Investment Management State Street Bank and Trust Company North America Inc Sands Capital Management Inc Investment Advisers Schroder Investment Management Cambridge Associates (Japan) Limited Société Générale Asset Management Investment Managers UK Limited Adams Street Partners LLC TT International Investment Aberforth Partners Management Limited Alex Brown Investment Management LP UBS Global Asset Management (UK) Limited Atlantis Fund Management Wellington Management Co. LLP (Guernsey) Limited Baillie Gifford & Co. Investment Property Managers Barclays Global Investors Limited Bidwells Brandes Investment Partners LLP Cluttons Brown Investment Advisory & Trust Company Cushman & Wakefield Healey & Baker Capital International Limited io Group Limited Clay Finlay Inc Solicitors Deutsche Asset Management Limited CMS Cameron McKenna Deutsche Investment Management Testa Hurwitz & Thibeault Americas Inc Fidelity Pensions Management Limited First State Investment Management (UK) Limited Gartmore Investment Management plc International Asset Management Limited Investec Investment Management Limited JF Asset Management Limited JO Hambro Capital Management Limited 16233 WellcomeAW 17-02 27/2/04 10:29 am Page 4 4 Chairman’s Statement For the third year in succession I find myself Major activities New initiatives in our international portfolio reviewing a year of continuing volatility in In my fourth year as Chairman I know that include the launch of a £25 million equity markets around the world. Although the wide breadth of projects supported by programme, Animal Health in the Developing the Trust ended the year with an asset value the Trust makes it ever more difficult to single World, focusing on livestock diseases in the higher than at the start of the year, we have out particular activities for attention. A fuller developing world and the impact on human been affected by the reduction in value from picture of the last twelve months can be health and wellbeing. Under this initiative we the high points in 1999/2000 and the obtained from the Trustee’s Report and the envisage funding a spectrum of projects over continuing global political and economic separate Annual Review, so here I am focusing the next two years from biomedical research uncertainty. In February 2003, therefore, on events or activities that have generated and public engagement projects to activities the Board of Governors approved a revised either particular UK or international that strengthen the translation of research financial plan. From a previously planned level recognition, or fundamentally altered the outcomes into practical benefits. In partnership of expenditure of around £500 million per ability of the Trust to ‘make a difference’. with the governments of Australia and New annum, this revision now enables us to Zealand we launched the Asia-Pacific scheme, A new synchrotron is an essential facility for commit grant and direct activity expenditure to tackle the health problems of developing biomedical research in the UK, so I am glad of approximately £400 million per annum. countries in the Asia-Pacific region. to report that the Diamond ground breaking We are confident that this meets the twin Negotiations are in hand to award up to ceremony took place in March.This marked objectives of managing our assets to provide £6 million during the forthcoming year. the start of the construction phase of for both future long term growth and Diamond, a jointly funded project between In the UK we implemented the decision supporting a substantial current level of the Trust and the UK Government (through taken in 2002 to integrate the Trust’s support charitable giving. the Council for the Central Laboratory for for translating biomedical research into We have taken stock of our activities and the Research Councils) to build a new third therapeutic or diagnostic outcomes, previously considerable staff effort was put into a generation synchrotron light source in the channelled through Catalyst BioMedica comprehensive cross-organisational review. UK.When it commences operation in January Limited, into a new internal Technology Much work was done to examine our 2007, Diamond will provide cutting-edge Transfer Division.The Division was successfully activities against our aims, to ensure research facilities for scientists from both the life established with the objective of maximising continuing support for the Trust’s mission. and physical sciences from the UK and abroad. the impact of research innovations on human As a result of the review some of our and animal health, by facilitating their An entirely different area of partnership activities have been scaled back, others development to the point at which they can with the UK Government led to us being strengthened, and a handful have been be funded by the financial market.The first of joined by Stephen Twigg MP,Minister for stopped.We are confident that we can its University and Strategic Translation Awards Young People and Learning, for the launch, continue to support a diverse portfolio of were made in September and again more in December 2002, of the National Science grant schemes and activities across the details of the activities in this area are set out Learning Centre competition.This Centre will spectrum of our interests whilst continuing in the Trustee’s Report. be the hub of a National Network of to maintain our asset base for the future. Learning Centres that will provide continuing Last year we were fortunate to be able to During the year we said farewell to professional development to school teachers secure the archive of Francis Crick, and this Dr Mike Dexter as Director, who made an of the sciences.This will enhance the careers year I was pleased to see that material from invaluable contribution to the Trust during and teaching skills of such teachers and aims the archive went on display for the first time his five year term of office, and welcomed his to boost the interest and enthusiasm of future as part of an exhibition and associated events successor, Dr Mark Walport, who took up the pupils for science, encouraging new generations held at the Trust to celebrate the 50th position
Load more

Recommended publications
  • ANNUAL REVIEW 1 October 2005–30 September
    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
    [Show full text]
  • CRISPR and Beyond Perturbations at Scale to Understand Genomes 2-4
    CRISPR and Beyond Perturbations at Scale to Understand Genomes 2-4 September 2019 Wellcome Genome Campus, UK Lectures to be held in the Francis Crick Auditorium Lunch and dinner to be held in the Hall Restaurant Poster sessions to be held in the Conference Centre Spoken presentations - If you are an invited speaker, or your abstract has been selected for a spoken presentation, please give an electronic version of your talk to the AV technician. Poster presentations – If your abstract has been selected for a poster, please display this in the Conference Centre on arrival. Conference programme Monday, 2 September 2019 11:45-12:50 Registration 12:50-13:00 Welcome and introductions Leopold Parts, Wellcome Sanger Institute UK 13.00-14.00 Keynote lecture Allan Bradley Kymab, UK 14:00-15:30 Session 1: Understanding impact of coding variations Chair: Leopold Parts, Wellcome Sanger Institute UK 14:00 New approaches for addressing the effect of genetic variation at scale Douglas Fowler University of Washington, USA 14:30 Tools for systematic proactive functional testing of human missense variants Frederick Roth University of Toronto 15:00 The mutational landscape of a prion-like domain Benedetta Bolognesi Institute for Bioengineering of Catalonia, Spain 15:15 Functional determination of all possible disease-associated variants in a region of CARD11 using saturation genome editing Richard James University of Washington, USA 15:30-16:00 Afternoon tea 16:00-17:30 Session 2: Measuring consequences of non-coding variation Chair: Lea Starita, University
    [Show full text]
  • Strategic Plan 2011-2016
    Strategic Plan 2011-2016 Wellcome Trust Sanger Institute Strategic Plan 2011-2016 Mission The Wellcome Trust Sanger Institute uses genome sequences to advance understanding of the biology of humans and pathogens in order to improve human health. -i- Wellcome Trust Sanger Institute Strategic Plan 2011-2016 - ii - Wellcome Trust Sanger Institute Strategic Plan 2011-2016 CONTENTS Foreword ....................................................................................................................................1 Overview .....................................................................................................................................2 1. History and philosophy ............................................................................................................ 5 2. Organisation of the science ..................................................................................................... 5 3. Developments in the scientific portfolio ................................................................................... 7 4. Summary of the Scientific Programmes 2011 – 2016 .............................................................. 8 4.1 Cancer Genetics and Genomics ................................................................................ 8 4.2 Human Genetics ...................................................................................................... 10 4.3 Pathogen Variation .................................................................................................. 13 4.4 Malaria
    [Show full text]
  • Fiona Fox Chief ExecuVe
    Fiona Fox Chief Execu+ve Set up in 2002 aer things went very wrong: - MMR & au;sm - GM crops - BSE - Animal research AIMS Vision Policy decisions and public debate informed by accurate, evidence-based scien7fic informaon in the news media Mission To make it easier for journalists to access the best science when stories hit the headlines and to ensure that more scien7sts engage with the media when stories hit the headlines Values Reliable, fast, accurate, authoritave, independent, media savvy SMC Philosophy " We’ll get the media to ‘DO’ science better when scientists ‘DO’ media better " Animal research in the UK media 1. The Bad Old Days Reac;ng to animal extremism 1980s – 1990s - Almost every story is on extremism - Only a handful of scien;sts prepared to speak out - Animal research covered by general and polical reporters - Funders and government stay quiet Legislave, judicial & Animal ac;vist / extremist ac;vity Science & medical governmental acon community acon 1997 (July) Consort Kennels in Hereford, a laboratory beagle breeder, closes aer a 10-month animal rights campaign including the theG of 26 beagles. 1999 (August) Hillgrove Farm in Oxfordshire, the UK's only commercial breeder of laboratory cats, closes aer a violent three year campaign. (Jan) Cambridge University abandons plan 2004 for new primate laboratory aer intense campaigning. (Oct) Darley Oaks Farm in Staffordshire closes its guinea pig breeding business aer a violent six-year campaign including digging up the grave of Gladys Hammond, the owners’ mother-in-law, sparking
    [Show full text]
  • 158273472.Pdf
    ANNUAL .2003REPCOLD SPRING HARBOR LABORATORY .1; ANNUAL REPORT 2003 © 2004 by Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory One Bungtown Road Cold Spring Harbor, New York 11724 Web Site: www.cshl.edu Managing Editors Jeff Picarello, Lisa Becker Production Editor Rena Steuer Copy Editor Dorothy Brown Development Manager Jan Argentine Project Coordinators Maria Falasca, Nora Rice Production Manager Denise Weiss Desktop Editor Susan Schaefer Nonscientific Photography Miriam Chua, Bill Geddes Cover Designer Denise Weiss Book Designer Emily Harste Front cover: McClintock Laboratory (right) and Carnegie Library (left) (photos by Miriam Chua) Back cover: Magnolia Kobus on grounds of Cold Spring Harbor Laboratory (photo by Bruce Stillman) Section title pages: Miriam Chua Contents Officers of the Corporation/Board of Trusteesiv-v Governancevi Committees vii Edwin Marks (1926-2003) viii PRESIDENT'S REPORT Highlights5 CHIEF OPERATING OFFICER'S REPORT 25 50TH ANNIVERSARY OF THE DOUBLE HELIX 29 RESEARCH 47 Cancer: Gene Expression 49 Cancer: Genetics 74 Cancer: Cell Biology 106 Bioinformatics and Genomics 134 Neuroscience152 Plant Development and Genetics 199 CSHL Fellows 212 Author Index 217 WATSON SCHOOL OF BIOLOGICAL SCIENCES 219 Dean's Report 221 Courses 238 Undergraduate Research Program245 Partners for the Future 248 Nature Study 249 COLD SPRING HARBOR LABORATORY MEETINGS AND COURSES 251 Academic Affairs253 Symposium on Quantitative Biology 255 Meetings 258 Postgraduate Courses295 Seminars 353 BANBURY CENTER 355 Director's Report357 Meetings 365 DOLAN DNA LEARNING CENTER 403 Director's Report 405 Workshops, Meetings, and Collaborations 418 COLD SPRING HARBOR LABORATORY PRESS 425 Publications 426 Executive Director's Report 427 FINANCE 431 History of the CSHL Endowment 433 Financial Statements 444 Financial Support448 Grants448 Institutional Advancement 457 Capital and Program Contributions 458 Watson School of Biological Sciences Capital Campaign 459 Annual Contributions 460 LABORATORY STAFF 474 III Officers of the Corporation William R.
    [Show full text]
  • Human Genetics 1990–2009
    Portfolio Review Human Genetics 1990–2009 June 2010 Acknowledgements The Wellcome Trust would like to thank the many people who generously gave up their time to participate in this review. The project was led by Liz Allen, Michael Dunn and Claire Vaughan. Key input and support was provided by Dave Carr, Kevin Dolby, Audrey Duncanson, Katherine Littler, Suzi Morris, Annie Sanderson and Jo Scott (landscaping analysis), and Lois Reynolds and Tilli Tansey (Wellcome Trust Expert Group). We also would like to thank David Lynn for his ongoing support to the review. The views expressed in this report are those of the Wellcome Trust project team – drawing on the evidence compiled during the review. We are indebted to the independent Expert Group, who were pivotal in providing the assessments of the Wellcome Trust’s role in supporting human genetics and have informed ‘our’ speculations for the future. Finally, we would like to thank Professor Francis Collins, who provided valuable input to the development of the timelines. The Wellcome Trust is a charity registered in England and Wales, no. 210183. Contents Acknowledgements 2 Overview and key findings 4 Landmarks in human genetics 6 1. Introduction and background 8 2. Human genetics research: the global research landscape 9 2.1 Human genetics publication output: 1989–2008 10 3. Looking back: the Wellcome Trust and human genetics 14 3.1 Building research capacity and infrastructure 14 3.1.1 Wellcome Trust Sanger Institute (WTSI) 15 3.1.2 Wellcome Trust Centre for Human Genetics 15 3.1.3 Collaborations, consortia and partnerships 16 3.1.4 Research resources and data 16 3.2 Advancing knowledge and making discoveries 17 3.3 Advancing knowledge and making discoveries: within the field of human genetics 18 3.4 Advancing knowledge and making discoveries: beyond the field of human genetics – ‘ripple’ effects 19 Case studies 22 4.
    [Show full text]
  • The Changing Governance of Genetic Intervention Technologies
    The Changing Governance of Genetic Intervention Technologies An Analysis of Legal Change Patterns, Drivers, Impacts, and a Proposed Reform Neil Harrel Thesis submitted to the University of Ottawa in partial fulfillment of the requirements for the Doctorate in Philosophy (Ph.D.) degree in Law Faculty of Law University of Ottawa © Neil Harrel, Ottawa, Canada, 2021 . Abstract Major breakthroughs in biotechnology are leading to the emergence of novel methods to select and alter future individuals’ genomes. Genetic intervention technology is evolving from the medical practice of screening for life-threatening congenital malformations to the selection against embryos that might develop mild disabilities. Scientific research suggests that heritable genome-editing technology would enable the custom alteration and the enhancement of human biological characteristics, including appearance, athletic and intellectual abilities. These novel developments and their potential long-term impacts raise the question of how effective are the laws on genetic interventions in setting limits to rapidly evolving biotechnologies. This thesis examines genetic intervention laws in the United Kingdom and France and shows it exhibits a pattern of continuous legal changes over the past several years to permit a broadening range of genetic interventions that were previously prohibited. This pattern is characterized by the regulatory licensing of genetic interventions that specific legal restrictions have sought to disallow, such as screening against conditions that are mild, treatable and not predominantly determined by genes. Moreover, governments are currently considering replacing their bans on inheritable human genetic modification with regulations that will allow the alteration of genes linked to conditions deemed “serious” and for “therapeutic” purposes. This proposed regulatory model would enable licensing the very same type of genomic alterations intended to be prohibited – genetic enhancements of human physiological and cognitive capabilities.
    [Show full text]
  • Wellcome Trust Annual Report and Financial Statements 2009
    ANNUAL REPORT AND FINANCIAL STATEMENTS 2009 A charity registered in England, no. 210183. 1 TABLE OF CONTENTS Page Chairman’s Statement 2 Trustee’s Report 4 Objects, Mission and Aims 4 Financial Summary 5 Review of Past and Future Activities 7 Investment Summary 10 Remuneration Report 19 Structure, Governance and Policy 21 Independent Auditors’ Report 28 Consolidated Statement of Financial Activities 29 Consolidated Balance Sheet 30 Statement of Financial Activities of the Trust 31 Balance Sheet of the Trust 32 Consolidated Cash Flow Statement 33 Notes to the Financial Statements 34 Reference and Administrative Details 73 2 CHAIRMAN’S STATEMENT In February 2009 I had the great privilege of spending majority of those attending the continuing professional time with colleagues at our Major Overseas Programme in development courses at the Centre have indicated Vietnam. Based in the Hospital for Tropical Diseases, Ho the experience had a significant positive impact on Chi Minh City, researchers are improving our understanding themselves, their school or their pupils, and many say of many of the world’s deadliest diseases, including malaria, they have developed new skills in teaching methods. dengue, typhoid, tetanus and tuberculosis. It is a sobering experience to witness first hand the debilitating effects of Expenditure and investments diseases that we do not see in our day to day lives. In the clinical wards we visited, the important and integral role that The many exciting projects outlined in our Trustee’s research plays in improving patient care and quality of life Report would not be possible without the privilege of for so many individuals and their families is abundantly clear.
    [Show full text]
  • Annu Al Review
    THE WELLCOME TRUST THE WELLCOME THE WELLCOME TRUST THE WELLCOME TRUST ANNUAL REVIEW ANNUAL REVIEW ANNUAL 1999/2000 1 October 1999 1 October1999 _ 30 September2000 The Wellcome Trust is an independent research-funding charity, established under the will of Sir Henry Wellcome in 1936.It is funded from a private endowment, which is managed with long-term stability and growth in mind. Its mission is to foster and promote research with the aim of improving human and animal health. Its work covers four areas: Knowledge improving our understanding of human and animal biology in health and disease, and of the past and present role of medicine in society. Resources providing exceptional researchers with the infrastructural and career support they need to fulfil their potential. Translation ensuring maximum health benefits are gained from biomedical research. Public engagement raising awareness of the medical, ethical and social implications of biomedical science. CONTENTS Highlights of the year 2 Director’s Introduction 4 Planning for the Future 6 PART 1 MAKING A DIFFERENCE 1999–2000 Knowledge Base 8 Resources 14 Translation 20 Public Engagement 26 PART 2 RESEARCH REPORTS Making faces 32 Tipping the balance 35 Starfish and mousetraps 36 The hidden danger 40 Capping it all 43 Thinking inside the box 44 Why art? 48 The past is before us 50 Birth of a cell 54 Breaking the cycle 57 Cross-talking networks 60 PART 3 A YEAR IN THE TRUST UK Funding 64 Clinical and Careers 66 Centres and Indirectly Managed Major Initiatives 68 International Funding 70 Directly
    [Show full text]
  • Paterson Institute for Cancer Research SCIENTIFIC REPORT 2006 Leukapheresis Blood Product Is Depleted of CD25 + Lymphocytes Prior to Infusion Back Into the Patient
    Paterson Institute for Cancer Research SCIENTIFIC REPORT 2006 Leukapheresis blood product is depleted of CD25 + lymphocytes prior to infusion back into the patient. CD4 +CD25 + regulatory T-cells are thought to be instrumental in allowing a growing cancer to evade immunological attack and the rationale behind this clinical trial is that their removal may unmask an anti-tumour immune response in patients with cancer (See Biological Immune and Gene Therapy Group report on page 36) . Illustration Credits Many illustrations in this report were taken by Jenny Varley and Paul Cliff Cancer Research UK Paterson Institute for Cancer Research SCIENTIFIC REPORT 2006 Cancer Research UK Paterson Institute for Cancer Research Scientific Report 2006 Edited by Professor Jenny Varley, Assistant Director (Research) Design & Layout by Mark Wadsworth (Web & Graphic Designer) Paterson Institute for Cancer Research Wilmslow Road, Manchester M20 4BX Tel: 0161 446 3156 http://www.paterson.man.ac.uk ISSN 1740-4525 Copyright © 2006 Cancer Research UK Printed by Paramount Print Cancer Research UK Registered Charity No. 1089464 Registered as a company limited by guarantee in England and Wales No. 4325234 Registered address 61 Lincoln’s Inn Fields, London WC2A 3PX Tel +44 (0) 20 7242 0200 http://www.cancerresearchuk.org Contents Director’s Introduction . 6 The Manchester Cancer Research Centre. 8 The Paterson Institute for Cancer Research Bioinformatics Group ........................................................................ Crispin Miller . 10 Carcinogenesis
    [Show full text]
  • Springer A++ Viewer
    PublisherInfo PublisherName : BioMed Central PublisherLocation : London PublisherImprintName : BioMed Central 130591474-760XGenome BiologyGenome BiolLife SciencesAnimal Genetics and GenomicsHuman GeneticsPlant Genetics & GenomicsMicrobial Genetics and GenomicsBioinformaticsEvolutionary BiologyBiomedical and Life Sciences221211343 CoverDate : 2001–12– The Author(s)2001 The genome has landed - let the debate begin ArticleInfo ArticleID : 3976 ArticleDOI : 10.1186/gb-spotlight-20010212-01 ArticleCitationID : spotlight-20010212-01 ArticleSequenceNumber : 47 ArticleCategory : Research news ArticleFirstPage : 1 ArticleLastPage : 2 RegistrationDate : 2001–02–12 ArticleHistory : OnlineDate : 2001–02–12 ArticleCopyright : BioMed Central Ltd2001 ArticleGrants : ArticleContext : 130592211 Pete Moore Email: [email protected] LONDON Sequencing the human genome has been likened to landing on the moon. Two decades ago most people laughed at the prospect. One decade ago the task looked achievable but would be unbelievably slow. Then, a couple of years back we had some 5% of the code and the first draft. In 1998, when Craig Venter set up his own research unit and privatised the sequencing program, he fired a starting pistol. While private investors poured money into Venter's Celera Genomics, governments and the Wellcome Trust were forced to divert streams of cash into the race. The publicly funded Human Genome Project (HGP) was eager to publish a sequence of the genome, and quash any attempt to gain ownership of the information via patenting. The result has been two-fold, says Denis Alexander, head of the Molecular Immunology Programme at the Babraham Institute outside Cambridge, UK. First, having two separate efforts has undeniably accelerated the pace of research, knocking a couple of years off the anticipated time-scale. But second, he like many believes that the high-profile scrap has probably damaged public confidence or public perceptions of science.
    [Show full text]
  • Leading the Way
    Leading the way Highlights 2018/19 World-class 02 research and What we do innovation 02 Director’s Introduction that impacts 04 At a Glance people’s lives Through our cutting-edge infrastructure, scientific independence and innovative ideas we engage in long-term exploratory projects that drive forward science Wherever you see this dark blue text or yellow, click to find more information. Read more about our ground-breaking research into Parasites and Microbes Page 26 sanger.ac.uk What we do Our work Our approach Other information 08 Our work 10 Cancer, Ageing and Somatic Mutation 16 Cellular Genetics 20 Human Genetics 26 Parasites and Microbes 34 Tree of Life 40 Our approach 42 Scale 44 Innovation 46 Culture 48 Influence 52 50 Connections Other info 52 Image Credits 53 Institute Information Wellcome Sanger Institute Highlights 2018/19 1 What we do One such project is the UK Biobank Director’s Vanguard project, where our sequencing pipeline is delivering 50,000 volunteers’ Introduction whole-genome sequences to aid genetic he past year has been one of great exploration of health and disease. joy and sadness: we celebrated our By marrying the wealth of genomic data 25th anniversary and we mourned T with electronic health records and other the death of our first director, John Sulston. molecular characterisation tools, our Under John’s guidance, the Sanger Institute researchers have discovered new gene determined one-third of the human reference variants associated with osteoarthritis, genome, providing a fundamental gift to life developed prognostic calculators for science research worldwide. cancer, and created an artificial intelligence It seemed most fitting to seek to make that predicts new pathogen emergence.
    [Show full text]